Effectiveness of antipsychotic treatments for schizophrenia: Interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol

Journal of Clinical Psychiatry

Volumn 65, Issue 3, 2004, Pages 312-321

  Dossenbach, Martin ^a   Erol, Almila ^b   Kessaci, Mohand El Mahfoud ^c   Shaheen, Mostafa O ^d   Sunbol, Mohammed M ^e   Boland, Jason ^f   Hodge, Andrew ^f   O'Halloran, Ruth A ^f   Bitter, Istvan ^a  

^a Eli Lilly GesmbH   (Austria)

^b ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

^c Cairo University Hospital ^*

^d CAIRO UNIVERSITY   (Egypt)

^e ELI LILLY AUSTRALIA PTY LTD   (Australia)

^f SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; DIBENZOTHIAZEPINE DERIVATIVE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; ARTICLE; CHEMICALLY INDUCED DISORDER; COGNITIVE DEFECT; COMPARATIVE STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DYSKINESIA; FEMALE; HOSPITALIZATION; HUMAN; HYPERPROLACTINEMIA; INTERNATIONAL CLASSIFICATION OF DISEASES; MALE; OBSERVATION; PROSPECTIVE STUDY; QUESTIONNAIRE; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; COGNITION DISORDERS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIBENZOTHIAZEPINES; DYSKINESIA, DRUG-INDUCED; FEMALE; HALOPERIDOL; HUMANS; HYPERPROLACTINEMIA; INTERNATIONAL CLASSIFICATION OF DISEASES; MALE; OBSERVATION; PROSPECTIVE STUDIES; QUESTIONNAIRES; RISPERIDONE; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; WEIGHT GAIN;

EID: 2342536399     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v65n0305     Document Type: Article

References (57)

1. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Schizophrenia. Am J Psychiatry 1997;154(suppl 4):1-63 (Pubitemid 27152428)
2. Bassett AS, Addington D. Canadian clinical practice guidelines for the treatment of schizophrenia. Can J Psychiatry 1998;43(suppl 2):25-40
3. Lehman AF, Steinwachs DM. The schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull 1998;24:1-10
4. Miller AL, Chiles JA, Chiles JK, et al. The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms. J Clin Psychiatry 1999;60:649-657 (Pubitemid 29503644)
5. Kennedy A, Jain S, Vinogradov S. Atypical antipsychotics for schizophrenia: their collective role and comparative profiles. Formulary 2001;36:500-517 (Pubitemid 32656142)
6. Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 2002;16:23-45 (Pubitemid 34151336)
7. Tandon R, Jibson MD. Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology 2003;28(suppl 1):9-26 (Pubitemid 36015659)
8. Schillevoort I, de Boer A, Herings RM, et al. Risk of extrapyramidal syndromes with haloperidol, risperidone, or olanzapine. Ann Pharmacother 2001;35:1517-1522 (Pubitemid 34027445)
9. Leucht S, Pitschel-Walz G, Abraham D, et al. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res 1999;35:51-68 (Pubitemid 29023554)
10. Leucht S, Wahlbeck K, Hamann J, et al. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003;361:1581-1589 (Pubitemid 36578993)
11. Geddes J, Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000;321:1371-1376
12. Thornley B, Adams C. Content and quality of 2000 controlled trials in schizophrenia over 50 years. BMJ 1998;317:1181-1184
13. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000;342:1887-1892 (Pubitemid 30419054)
14. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000;342:1878-1886 (Pubitemid 30419053)
15. Emsley RA, Roberts MC, Rataemane S, et al. Ethnicity and treatment response in schizophrenia: a comparison of 3 ethnic groups. J Clin Psychiatry 2002;63:9-14 (Pubitemid 34113480)
16. Sacristan JA, Soto J, Galende I, et al. A review of methodologies for assessing drug effectiveness and a new proposal: randomized database studies. Clin Ther 1997;19:1510-1517 (Pubitemid 28133284)
17. Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ 1996;312:1215-1218 (Pubitemid 26136714)
18. Chouinard G, Kopala L, Labelle A, et al. Phase-IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia. The RIS-CAN-3 Study Group. Can J Psychiatry 1998;43:1018-1025 (Pubitemid 29063066)
19. Gomez JC, Sacristan JA, Hernandez J, et al, for the EFESO Study Group. The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). J Clin Psychiatry 2000;61:335-343 (Pubitemid 30345934)
20. Haro JM, Edgell ET, Jones PB, et al. The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment. Acta Psychiatr Scand 2003;107:222-232 (Pubitemid 36250283)
21. Bobes J, Rejas J, Garcia-Garcia M, et al. Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. Schizophr Res 2003;62:77-88 (Pubitemid 36588706)
22. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
23. Haro JM, Kamath SA, Ochoa S, et al. The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. SOHO Study Group. Acta Psychiatr Scand Suppl 2003;416:16-23 (Pubitemid 41737784)
24. Beasley CM Jr, Hamilton SH, Crawford AM, et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 1997;7:125-137 (Pubitemid 27240346)
25. Volavka J, Czobor P, Sheitman B, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002;159:255-262 (Pubitemid 34126903)
26. Tollefson GD, Sanger TM. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 1997;154:466-474 (Pubitemid 27147598)
27. Gomez JC, Crawford AM. Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter international trial. J Clin Psychiatry 2001;62(suppl 2):6-11 (Pubitemid 32154134)
28. Tollefson GD, Sanger TM, Lu Y, et al. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 1998;55:250-258 (Pubitemid 28128612)
29. Purdon SE, Jones BDW, Stip E, et al, for The Canadian Collaborative Group for Research in Schizophrenia. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch Gen Psychiatry 2000;57:249-258
30. Maguire GA. Comprehensive understanding of schizophrenia and its treatment. Am J Health Syst Pharm 2002;59:S4-11 (Pubitemid 34971265)
31. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-418 (Pubitemid 27414397)
32. Tollefson GD, Andersen SW, Tran PV. The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone. Biol Psychiatry 1999;46:365-373 (Pubitemid 29335917)
33. Gureje O, Miles W, Keks N, et al. Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand. Schizophr Res 2003;61:303-314 (Pubitemid 36519178)
34. Kasper S, Rosillon D, Duchesne I. Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): efficacy and tolerability results of an international naturalistic study. Int Clin Psychopharmacol 2001;16:179-187 (Pubitemid 32612515)
35. Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001;158:765-774 (Pubitemid 32429846)
36. Sacristan JA, Gomez JC, Montejo AL, et al. Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio Farmacoepidemiologico en la Esquizofrenia con Olanzapina. Clin Ther 2000;22:583-599
37. Arvanitis LA, Miller BG. Multiple fixed doses of Seroquel (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997;42:233-246 (Pubitemid 27325811)
38. Borison RL, Arvanitis LA, Miller BG. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. US Seroquel Study Group. J Clin Psychopharmacol 1996;16:158-169
39. Small JG, Hirsch SR, Arvanitis LA, et al. Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry 1997;54:549-557 (Pubitemid 27258553)
40. Emsley RA, Raniwalla J, Bailey PJ, et al. A comparison of the effects of quetiapine (Seroquel) and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group. Int Clin Psychopharmacol 2000;15:121-131 (Pubitemid 30326047)
41. Mullen J, Jibson MD, Sweitzer D. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin Ther 2001;23:1839-1854 (Pubitemid 33121972)
42. Tran PV, Dellva MA, Tollefson GD, et al. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry 1997;58:205-211 (Pubitemid 27242007)
43. Tollefson GD, Beasley CM Jr, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457-465 (Pubitemid 27147597)
44. Bhana N, Foster RH, Olney R, et al. Olanzapine: an updated review of its use in the management of schizophrenia. Drugs 2001;61:111-161 (Pubitemid 32108327)
45. Balestrieri M, Vampini C, Bellantuono C. Efficacy and safety of novel antipsychotics: a critical review. Hum Psychopharmacol 2000;15:499-512 (Pubitemid 30944001)
46. Stip E. Novel antipsychotics: issues and controversies: typicality of atypical antipsychotics. J Psychiatry Neurosci 2000;25:137-153 (Pubitemid 30233551)
47. David SR, Taylor CC, Kinon BJ, et al. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther 2000;22:1085-1096 (Pubitemid 30747129)
48. Cutler AJ. Sexual dysfunction and antipsychotic treatment. Psychoneuroendocrinology 2003;28(suppl 1):69-82 (Pubitemid 36015662)
49. Kinon BJ, Gilmore JA, Liu H, et al. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology 2003;28(suppl 2):55-68 (Pubitemid 36332229)
50. Huang ML, Van Peer A, Woestenborghs R, et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 1993;54:257-268 (Pubitemid 23294526)
51. Maguire GA. Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. J Clin Psychiatry 2002;63(suppl 4):56-62 (Pubitemid 34242111)
52. Hamner MB, Arvanitis LA, Miller BG, et al. Plasma prolactin in schizophrenia subjects treated with Seroquel (ICI 204,636). Psychopharmacol Bull 1996;32:107-110
53. Casey DE, Zorn SH. The pharmacology of weight gain with antipsychotics. J Clin Psychiatry 2001;62(suppl 7):4-10 (Pubitemid 32402180)
54. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-1696 (Pubitemid 29517559)
55. Kinon BJ, Basson BR, Gilmore JA, et al. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 2001;62:92-100 (Pubitemid 32199865)
56. Czobor P, Volavka J, Sheitman B, et al. Antipsychotic-induced weight gain and therapeutic response: a differential association. J Clin Psychopharmacol 2002;22:244-251 (Pubitemid 34546838)
57. Nasrallah H. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology 2003;28(suppl 1):83-96 (Pubitemid 36015663)